[go: up one dir, main page]

FR2828104B1 - Utilisation d'inhibiteurs du facteur de croissance epidermique liant l'heparine ou d'inhibiteurs de ses recepteurs pour la preparation de medicaments utiles pour traiter le myelome - Google Patents

Utilisation d'inhibiteurs du facteur de croissance epidermique liant l'heparine ou d'inhibiteurs de ses recepteurs pour la preparation de medicaments utiles pour traiter le myelome

Info

Publication number
FR2828104B1
FR2828104B1 FR0110354A FR0110354A FR2828104B1 FR 2828104 B1 FR2828104 B1 FR 2828104B1 FR 0110354 A FR0110354 A FR 0110354A FR 0110354 A FR0110354 A FR 0110354A FR 2828104 B1 FR2828104 B1 FR 2828104B1
Authority
FR
France
Prior art keywords
inhibitors
myeloma
heparin
receptors
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0110354A
Other languages
English (en)
Other versions
FR2828104A1 (fr
Inventor
Bernard Klein
Vos John De
Yue Dan Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre Hospitalier Universitaire de Montpellier
Original Assignee
Centre Hospitalier Universitaire de Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Universitaire de Montpellier filed Critical Centre Hospitalier Universitaire de Montpellier
Priority to FR0110354A priority Critical patent/FR2828104B1/fr
Priority to JP2003518495A priority patent/JP2005504038A/ja
Priority to CA002459071A priority patent/CA2459071A1/fr
Priority to PCT/FR2002/002777 priority patent/WO2003013485A1/fr
Priority to US10/484,819 priority patent/US20040254144A1/en
Priority to EP02794618A priority patent/EP1411907A1/fr
Publication of FR2828104A1 publication Critical patent/FR2828104A1/fr
Application granted granted Critical
Publication of FR2828104B1 publication Critical patent/FR2828104B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0110354A 2001-08-01 2001-08-01 Utilisation d'inhibiteurs du facteur de croissance epidermique liant l'heparine ou d'inhibiteurs de ses recepteurs pour la preparation de medicaments utiles pour traiter le myelome Expired - Fee Related FR2828104B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR0110354A FR2828104B1 (fr) 2001-08-01 2001-08-01 Utilisation d'inhibiteurs du facteur de croissance epidermique liant l'heparine ou d'inhibiteurs de ses recepteurs pour la preparation de medicaments utiles pour traiter le myelome
JP2003518495A JP2005504038A (ja) 2001-08-01 2002-08-01 ヘパリン結合性上皮増殖因子阻害剤又はその受容体の阻害剤の、骨髄腫の治療に有用な薬剤の調製のための使用
CA002459071A CA2459071A1 (fr) 2001-08-01 2002-08-01 Utilisation des inhibiteurs du facteur de croissance epidermique se liant 'a l'heparine ou de ses inhibiteurs de ses recepteurs dans la preparation de medicaments utiles pour traiter le myelome
PCT/FR2002/002777 WO2003013485A1 (fr) 2001-08-01 2002-08-01 Inhibiteurs des recepteurs de hb-egf (erbb) pour traiter le myelome
US10/484,819 US20040254144A1 (en) 2001-08-01 2002-08-01 Use of inhibitors of heparin-binding epidermal growth factor or inhibitors of its receptors for the preparation of drugs useful for treating myeloma
EP02794618A EP1411907A1 (fr) 2001-08-01 2002-08-01 Inhibiteurs des recepteurs de hb-egf (erbb) pour traiter le myelome

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0110354A FR2828104B1 (fr) 2001-08-01 2001-08-01 Utilisation d'inhibiteurs du facteur de croissance epidermique liant l'heparine ou d'inhibiteurs de ses recepteurs pour la preparation de medicaments utiles pour traiter le myelome

Publications (2)

Publication Number Publication Date
FR2828104A1 FR2828104A1 (fr) 2003-02-07
FR2828104B1 true FR2828104B1 (fr) 2005-06-24

Family

ID=8866206

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0110354A Expired - Fee Related FR2828104B1 (fr) 2001-08-01 2001-08-01 Utilisation d'inhibiteurs du facteur de croissance epidermique liant l'heparine ou d'inhibiteurs de ses recepteurs pour la preparation de medicaments utiles pour traiter le myelome

Country Status (6)

Country Link
US (1) US20040254144A1 (fr)
EP (1) EP1411907A1 (fr)
JP (1) JP2005504038A (fr)
CA (1) CA2459071A1 (fr)
FR (1) FR2828104B1 (fr)
WO (1) WO2003013485A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305284A3 (fr) * 2002-03-08 2012-11-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Utilisation de transactivateur de l'EGFR dans le cancer chez l'humain
EP1493445A1 (fr) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition de l'activation de l'EGFR, cette activation étant dépendante d'un ligand et étant induite par le stress
BRPI0817255A2 (pt) * 2007-09-26 2017-06-06 Amgen Inc proteínas de ligação a antígeno de fator de crescimento tipo fator de crescimento epidermal de ligação à heparina.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757056A (en) * 1984-03-05 1988-07-12 Hepar Industries, Inc. Method for tumor regression in rats, mice and hamsters using hexuronyl hexosaminoglycan-containing compositions
US6090794A (en) * 1990-04-19 2000-07-18 The General Hospital Corporation Inhibition of neurofibrosarcoma growth and angiogenesis
US5366874A (en) * 1992-01-02 1994-11-22 Board Of Regents, The University Of Texas System Molecular cloning and expression of biologically-active diphtheria toxin receptor
US6235884B1 (en) * 1993-06-15 2001-05-22 Scios Nova, Inc. Heparin binding mitogen with homology to epidermal growth factor (EGF)
EP0852587B1 (fr) * 1995-09-28 2009-02-25 Yeda Research And Development Co., Ltd. Peptides synthetiques inhibant l'activite de l'interleukine 6
US5876730A (en) * 1997-08-07 1999-03-02 Childrens Hospital Research Foundation Heparin-binding growth factor (HBGF) polypeptides
AU2002250352C1 (en) * 2001-04-02 2009-04-30 Genentech, Inc. Combination therapy
IL159177A0 (en) * 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof

Also Published As

Publication number Publication date
JP2005504038A (ja) 2005-02-10
WO2003013485A1 (fr) 2003-02-20
US20040254144A1 (en) 2004-12-16
FR2828104A1 (fr) 2003-02-07
EP1411907A1 (fr) 2004-04-28
CA2459071A1 (fr) 2003-02-20

Similar Documents

Publication Publication Date Title
NO20030603D0 (no) Behandling av hyperprolifererende sykdommer med epidermale, vekstfaktorreseptorantagonister
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
DE60235719D1 (de) Frauenhygieneartikel zur verabreichung von arzneimittel
ITMI20011083A0 (it) Dispositivo per l'igiene dentale
EP1482972A4 (fr) Traitement des troubles immunologiques au moyen des anticorps anti-cd30
ATE320257T1 (de) (s,s)-reboxetine zur behandlung chronischer schmerzen
FR2826256B1 (fr) Prothese pour epaule traumatique
ITMI20011194A0 (it) Reggiseno femminile autosupportato
FR2841470B1 (fr) Utilisation d'isoflavones pour la preparation de compositions topiques utiles pour favoriser l'amincissement et methode de traitement cosmetique associee
FR2863878B1 (fr) Utilisation d'ecdysteroides pour la preparation de compositions dermathologiques ou cosmetiques anti-chute de cheveux.
FR2833596B1 (fr) Procede de preparation de derives d'echinocandine
FR2828104B1 (fr) Utilisation d'inhibiteurs du facteur de croissance epidermique liant l'heparine ou d'inhibiteurs de ses recepteurs pour la preparation de medicaments utiles pour traiter le myelome
EP1578723A4 (fr) Procede pour l'elaboration d'oxazolidinones et procede d'utilisation correspondant
EP1572129A4 (fr) Derives d'amidine pour le traitement des amyloses
DZ3320A1 (fr) Complexe comprenant de l'eletriptane et de la sulphobutylether-cyclodextrine pour le traitement de la migraine
FR2811998B1 (fr) Utilisation d'heteroxylanes pour la preparation de compositions filmogenes
EP1303594A4 (fr) Vegf-b glycosylees et methode d'augmentation de la quantite de vegf-b solubles
EP1395593A4 (fr) Nouveaux derives de pyrazolopyrimidinethione, procedes de preparation de ceux-ci et utilisation comme agents therapeutiques pour les dysfonctionnements de l'erection
FR2844701B1 (fr) Materiel d'osteosynthese pour os longs, notamment pour l'osteosynthese d'un radius ou d'un cubitus
FR2826865B1 (fr) Cupule d'implant cotyloidien
FR2833967B1 (fr) Utilisation de bacteries lactiques pour la production d'alpha-cetoglutarate
SM200100008A (it) Dispositivo per il trattamento di preforme per l'ottenimento di contenitori in plastica
FR2832922B1 (fr) Prothese d'epaule
ITMI20011833A0 (it) Agenti che regolano la permeabilita' vascolare
FR2821558B1 (fr) Dispositif pour le traitement de l'air, en particulier l'aseptisation et/ou la desodorisation de l'air

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20070430